Saturday, March 08, 2025 | 01:56 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Jubilant Life Sciences receives final approval for Indomethacin ER Capsule 75mg

Image

Capital Market

From USFDA

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Indomethacin ER Capsule 75mg, which is a non-steriodal anti- inflammatory drug used for treatment of pain.

As on 30 June 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.

Powered by Capital Market - Live News

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 07 2015 | 11:12 AM IST

Explore News